To find more information on MyAV·¶H Early Phase Cancer Clinical Trials, including eligibility criteria, click theÌýhyperlinkedÌýLocal Project Reference (LRP)ÌýID, which will take you to the MyAV·¶H Find a Study database.
Ìý
ProMMiseA Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr. Rakesh Popat |
Drug Class/ Treatment: | Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate) |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
DTP3Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NFκB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3 | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | DTP3Ìý(GADD45β/MKK7 Inhibitor) |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
79635322MMY1001Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | JNJ-79635322Ìý-ÌýTrispecific Antibody |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
TCD17710First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell mat ration antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory lightchain amyloidosis (RRLCA) | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | SAR445514 (NK-Cell Engager (NKCE) Targeting BCMA) |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
CAMMA - GO42552An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 1) | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | Cevostamab (GO425552) -ÌýBi-specific T-Cell Engager Arm B - Combnation with Pomalidomide + Dexamethasone |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
BGB-11417-105A phase 1b/2 Dose-Escalation and Cohort-Expansion Study to determine the Safety and Efficacy of BGB11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | |
---|---|
Local Project Reference: | Ìý |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | BGB-11417 (BCL2 Inhibitor) Monotherapy, In Combination with Dexamethasone and In Combination with Dexamethasone/Carfilzomib |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
M24-108A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma | |
---|---|
Local Project Reference: | Ìý |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | ABBV-383Ìý(B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody) |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
Ìý
CA057-003 (CC-92480) An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Rakesh Popat |
Drug Class/ Treatment: | Mezigdomide (CC-92480) -ÌýCereblon (CRBN) E3 Ligase Modulating Drug (CELMoD) |
Patient Population: | Multiple Myeloma |
Trial Hosted By - NIHR MyAV·¶H Clinical Research Facility (CRF) |
Ìý